Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 26.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (9.1%)
  • Dividend yield for the last twelve months 3.2%
  • Free cash flow yield 0.1% (LTM)
  • Share price is 37.9% higher than minimum and 23.8% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (10.6x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $1.3 mln (-0.001% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (-0.9%)101.33
year average price 87.17  


year start price 103.55 2024-12-05

min close price 73.47 2025-05-14

max close price 105.66 2025-11-25

current price 101.33 2025-12-04
Common stocks: 2 528 810 012

Dividend Yield:  3.2%
FCF Yield LTM: 0.1%
EV / LTM EBITDA: 10.6x
EV / EBITDA annualized: 8.9x
Last revenue growth (y/y):  +3.7%
Last growth of EBITDA (y/y):  +49.7%
Historical revenue growth:  +3.0%
Historical growth of EBITDA:  +15.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 256 244
Net Debt ($m): 23 217
EV (Enterprise Value): 279 461
EBITDA LTM ($m): 26 386
EV / LTM EBITDA: 10.6x
Price to Book: 5.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-04businesswire.com

FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)

2025-12-03seekingalpha.com

Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-12-03seekingalpha.com

Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript

2025-12-01zacks.com

Here's Why Merck (MRK) is a Strong Momentum Stock

2025-12-01businesswire.com

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

2025-11-29fool.com

Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?

2025-11-26zacks.com

Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?

2025-11-24zacks.com

FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer

2025-11-21businesswire.com

Merck Recommends Rejection of Tutanota's “Mini-Tender” Offer

2025-11-21businesswire.com

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data